Curis to Present at Upcoming Healthcare Conferences in September

Rhea-AI Summary

Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), an oral IRAK4 inhibitor, has announced upcoming presentations at two major healthcare conferences in September 2025.

CEO James Dentzer will participate in a fireside chat at the Cantor Global Healthcare Conference on September 5, 2025, at 9:45 am ET, and deliver a company presentation at the H.C. Wainwright Global Investment Conference on September 10, 2025, at 10:00 am ET. Both presentations will be available via webcast on the company's investor relations website.

LEXINGTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:

The Cantor Global Healthcare Conference 2025 being held September 3 – 5, 2025. Presentation details are as follows:

• Format: Fireside Chat
• Date: Friday, September 5, 2025
• Time: 9:45 am ET
• Cantor webcast

The H.C. Wainwright 27^th Annual Global Investment Conference being held September 8 – 10, 2025. Presentation details are as follows:

• Format: Company Presentation
• Date: Wednesday, September 10, 2025
• Time: 10:00 am ET
• H.C. Wainwright webcast

Webcasts will be also available on the Curis website at www.curis.com in the 'Investors' section.

About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-upcoming-healthcare-conferences-in-september-302543939.html

SOURCE Curis, Inc.

FAQ

When is Curis (CRIS) presenting at the Cantor Global Healthcare Conference 2025?

Curis CEO James Dentzer will participate in a fireside chat on Friday, September 5, 2025, at 9:45 am ET at the Cantor Global Healthcare Conference.

What type of presentation will Curis (CRIS) give at the H.C. Wainwright Conference?

Curis will deliver a company presentation on Wednesday, September 10, 2025, at 10:00 am ET at the H.C. Wainwright Global Investment Conference.

Where can investors watch the Curis (CRIS) conference presentations?

Investors can access the webcasts of both presentations through the 'Investors' section of the Curis website at www.curis.com.

What is Curis's (CRIS) main drug development focus?

Curis is focused on developing emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor.